| The use of viscoelastic haemostatic assays in the manage... |
40 |
| Cobomarsen, an oligonucleotide inhibitor of miR- co-ordi... |
39 |
| Cytokine release syndrome and neurotoxicity after CD19 c... |
35 |
| Eculizumab in paroxysmal nocturnal haemoglobinuria and a... |
31 |
| A phase 2 study of modified lenalidomide, bortezomib and... |
30 |
| Haemostasis and innate immunity - a complementary relati... |
25 |
| Advances in understanding the pathogenesis of acquired a... |
23 |
| The full spectrum of Castleman disease: 273 patients stu... |
22 |
| Incidence of and risk factors for major haemorrhage in p... |
21 |
| How I manage patients with relapsed/refractory diffuse l... |
21 |
